PDC-E2 Activators
PDC-E2 activators constitute a diverse group of compounds that exert their influence on the activation of PDC-E2, a crucial protein involved in various cellular processes. These activators can be broadly categorized based on their primary mechanisms of action, targeting different signaling pathways and molecular events. One subgroup includes natural compounds such as betulinic acid and resveratrol, which modulate PDC-E2 through the activation of nuclear receptors like PPARγ and SIRT1. Betulinic acid activates PDC-E2 by enhancing PPARγ-mediated transcription, while resveratrol activates SIRT1, leading to the deacetylation and activation of PDC-E2. Another subgroup comprises synthetic compounds like GW501516 and T0070907, acting as indirect activators through the modulation of PPARδ and PPARγ, respectively. GW501516 enhances PDC-E2 activation by influencing the AMPK pathway via PPARδ activation, while T0070907 relieves PPARγ-mediated inhibition, allowing increased expression of PDC-E2.
The second major subgroup involves compounds that target various kinase pathways. Examples include SB203580, dorsomorphin, and LY294002. SB203580 disrupts the negative regulation imposed by p38 MAPK, leading to increased PDC-E2 expression. Dorsomorphin indirectly activates PDC-E2 by inhibiting AMPK, resulting in mTORC1-mediated activation. LY294002 modulates the PI3K/Akt pathway, upregulating FOXO3a and promoting PDC-E2 expression. Additionally, ursolic acid and troglitazone represent a subgroup influencing the Wnt/β-catenin and PPARγ pathways, respectively. Ursolic acid stabilizes β-catenin, enhancing the transcriptional activity of TCF/LEF transcription factors and promoting PDC-E2 expression. Troglitazone activates PDC-E2 by positively regulating its transcription through PPARγ binding. Lastly, the compounds A769662, AICAR, and rapamycin act on the AMPK and mTOR pathways, indirectly influencing PDC-E2 activation. A769662 and AICAR activate AMPK, promoting PDC-E2 expression through downstream transcriptional regulation, while rapamycin inhibits mTOR, relieving negative regulation and enhancing PDC-E2 activation. In summary, the class of PDC-E2 activators encompasses a spectrum of compounds targeting diverse signaling pathways, providing valuable insights into potential strategies for modulating PDC-E2 activity in cellular contexts.
SEE ALSO...
Items 1 to 10 of 14 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Betulinic Acid | 472-15-1 | sc-200132 sc-200132A | 25 mg 100 mg | $117.00 $344.00 | 3 | |
Betulinic acid, a natural compound found in plants, influences the PPARγ pathway. It activates PPARγ, leading to an increase in the expression of PDC-E2. PPARγ is known to interact with specific response elements in the promoter region of PDC-E2, thereby promoting its transcription and subsequent activation. | ||||||
Insulin | 11061-68-0 | sc-29062 sc-29062A sc-29062B | 100 mg 1 g 10 g | $156.00 $1248.00 $12508.00 | 82 | |
Insulin, a hormone released in response to elevated blood glucose levels, can activate PDC-E2 by dephosphorylating it. This activation promotes glucose utilization. | ||||||
Calcium | 7440-70-2 | sc-252536 | 5 g | $209.00 | ||
Elevated calcium levels can activate PDC-E2 through calcium-dependent kinases, facilitating increased ATP production via oxidative phosphorylation. | ||||||
GW501516 | 317318-70-0 | sc-202642 sc-202642A | 1 mg 5 mg | $82.00 $179.00 | 28 | |
GW501516, a PPARδ agonist, indirectly activates PDC-E2. It enhances PPARδ activity, which, in turn, modulates the AMPK pathway. This cascade of events results in increased phosphorylation and subsequent activation of PDC-E2. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580, a selective p38 MAPK inhibitor, influences the MAPK signaling pathway. By inhibiting p38 MAPK, it disrupts the negative regulation of PDC-E2 expression imposed by p38 MAPK. This interruption leads to increased expression and activation of PDC-E2. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
Resveratrol, a natural polyphenol, activates SIRT1, a NAD+-dependent deacetylase. SIRT1, in turn, deacetylates and activates PDC-E2 through a direct interaction. This activation enhances the enzymatic activity of PDC-E2, contributing to its functional activation. | ||||||
Dorsomorphin dihydrochloride | 1219168-18-9 | sc-361173 sc-361173A | 10 mg 50 mg | $186.00 $751.00 | 28 | |
Dorsomorphin, an AMPK inhibitor, affects the AMPK signaling pathway. Inhibition of AMPK by dorsomorphin results in the activation of mTORC1, which indirectly activates PDC-E2. The increased mTORC1 activity facilitates PDC-E2 activation through downstream signaling events. | ||||||
A-769662 | 844499-71-4 | sc-203790 sc-203790A sc-203790B sc-203790C sc-203790D | 10 mg 50 mg 100 mg 500 mg 1 g | $184.00 $741.00 $1076.00 $3417.00 $5304.00 | 23 | |
A769662, an AMPK activator, directly activates AMPK. Activated AMPK positively regulates the expression of PDC-E2 by modulating the transcription factors involved in the regulation of PDC-E2 gene expression. This direct activation results in the increased expression and subsequent activation of PDC-E2. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002, a PI3K inhibitor, disrupts the PI3K/Akt pathway. Inhibition of this pathway upregulates FOXO3a, a transcription factor that promotes PDC-E2 expression. Consequently, LY294002 indirectly activates PDC-E2 by modulating the PI3K/Akt/FOXO3a axis. | ||||||
AICAR | 2627-69-2 | sc-200659 sc-200659A sc-200659B | 50 mg 250 mg 1 g | $65.00 $280.00 $400.00 | 48 | |
AICAR, an AMPK activator, activates AMPK, leading to the downstream activation of PDC-E2. This activation occurs through the AMPK-mediated modulation of transcription factors involved in the regulation of PDC-E2 gene expression, resulting in increased expression and subsequent activation of PDC-E2. | ||||||